Graybug Vision
Corporate Events:Acquired by CALC w/ merger closed on March 20, 2023.
Company Details
Status: Private
Employees: 101-250
Location:
Redwood City, California, United States
Type:
sample
Technology:
sample
sample
About: March 20,2023
CalciMedica Inc. (CalciMedica) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need, today announced the closing of its previously announced merger with Graybug Vision, Inc. CalciMedica’s stock will commence trading on March 21, 2023 on the Nasdaq Global Market under the trading symbol “CALC”.
Immediately prior to the closing of the merger, CalciMedica completed the previously announced private placement of $10.3 million. With the closing of the merger, CalciMedica has approximately $34 million in cash and cash equivalents, which is expected to provide the company a cash runway into the second half of 2024 and fund the advancement of Auxora through clinical milestones in 2023,
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Graybug Vision | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.